Evidence map›Paper›PMID 37976458›Full record

ArticleBlood advances2024

Oxygen gradient ektacytometry-derived biomarkers are associated with acute complications in sickle cell disease.

Minke A E Rab, Celeste K Kanne, Camille Boisson, Jennifer Bos, Brigitte A van Oirschot, Maite E Houwing, Céline Renoux, Marije Bartels, Anita W Rijneveld, Erfan Nur and 8 more

Abstract read
In one paragraph

Article in Blood advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Investigation of Red Blood Cell Properties on Impedance Signatures Generated in a Coulter Counter.International journal for numerical methods in biomedical engineering · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Minke A E RabCentral Diagnostic Laboratory-Research, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.ORCID 0000-0002-8306-8726
Celeste K KanneDepartment of Pediatrics Emory University School of Medicine, Children's Healthcare of Atlanta, Atlanta, GA.
Camille BoissonLaboratory LIBM EA7424, University of Lyon 1, "Vascular Biology and Red Blood Cell" team, Lyon, France.ORCID 0000-0002-4208-8376
Jennifer BosCentral Diagnostic Laboratory-Research, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Brigitte A van OirschotCentral Diagnostic Laboratory-Research, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Maite E HouwingDepartment of Pediatric Hematology and Oncology, Erasmus Medical Center Sophia Children's Hospital, University Medical Center Rotterdam, Rotterdam, The Netherlands.ORCID 0000-0003-1152-7361
Céline RenouxLaboratory LIBM EA7424, University of Lyon 1, "Vascular Biology and Red Blood Cell" team, Lyon, France.
Marije BartelsVan Creveldkliniek, Divison of Internal Medicine and Dermatology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Anita W RijneveldDepartment of Hematology, Erasmus Medical Center, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Erfan NurDepartment of Hematology, Amsterdam University Medical Center, The Netherlands.ORCID 0000-0002-7069-930X
Marjon H CnossenDepartment of Pediatric Hematology and Oncology, Erasmus Medical Center Sophia Children's Hospital, University Medical Center Rotterdam, Rotterdam, The Netherlands.ORCID 0000-0003-1557-2995
Philippe JolyLaboratory LIBM EA7424, University of Lyon 1, "Vascular Biology and Red Blood Cell" team, Lyon, France.ORCID 0000-0002-2351-9441
Elie NaderLaboratory LIBM EA7424, University of Lyon 1, "Vascular Biology and Red Blood Cell" team, Lyon, France.ORCID 0000-0002-6054-2456
Romain FortLaboratory LIBM EA7424, University of Lyon 1, "Vascular Biology and Red Blood Cell" team, Lyon, France.ORCID 0000-0003-0773-3883
Philippe ConnesLaboratory LIBM EA7424, University of Lyon 1, "Vascular Biology and Red Blood Cell" team, Lyon, France.ORCID 0000-0002-9232-0268
Richard van WijkCentral Diagnostic Laboratory-Research, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Vivien A SheehanDepartment of Pediatrics Emory University School of Medicine, Children's Healthcare of Atlanta, Atlanta, GA.ORCID 0000-0003-2837-2255
Eduard J van BeersVan Creveldkliniek, Divison of Internal Medicine and Dermatology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.ORCID 0000-0002-3934-7189

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

abstractWe investigated the potential of the point of sickling (PoS; the pO2 tension at which red cells start to sickle), determined by oxygen gradient ektacytometry to serve as a biomarker associated with the incidence of acute sickle cell disease-related complications in 177 children and 50 adults. In the pediatric cohort, for every 10 mmHg increase in PoS reflecting a greater likelihood of sickling, the likelihood of an individual experiencing >1 type of acute complication increased; the adjusted odds ratio (aOR) was 1.65. For every 0.1 increase in minimum elongation index (EImin; reflecting improved red blood cell deformability at hypoxia), the aOR was 0.50. In the adult cohort, for every 10 mmHg increase in PoS, we found an aOR of 3.00, although this was not significant after correcting for multiple testing. There was a trend for an association between higher PoS and greater likelihood of vaso-occlusive episodes (VOEs; children aOR, 1.35; adults aOR, 2.22). In children, only EImin was associated with VOEs (aOR, 0.68). When data of both cohorts were pooled, significant associations with PoS and/or EImin were found for all acute complications, independently and when >1 type of acute complication was assessed. These findings indicate that oxygen gradient ektacytometry generates novel biomarkers and provides a rationale for further development of these biomarkers in the assessment of clinical severity, evaluation of novel therapies, and as surrogate clinical trial end points. These biomarkers may be useful in assessing efficacy of novel therapies like pyruvate kinase activators, voxelotor, and L-glutamine.

Indexed as

Anemia, Sickle CellOxygenAdultBiomarkersChildErythrocytesErythrocytes, AbnormalHumansBiomarkersOxygen

Identifiers

PMID37976458
PMCPMC10824684

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.